1Department of Neurological Surgery, Mayo Clinic, Rochester, Minnesota.
2Department of Neurosurgery, Inova Fairfax Hospital, Falls Church, Virginia.
J Neurosurg. 2023 Aug 4;140(2):420-429. doi: 10.3171/2023.5.JNS222557. Print 2024 Feb 1.
Petroclival meningiomas (PCMs) are challenging lesions to treat because of their deep location and proximity to critical neurovascular structures. Patients with these lesions commonly present because of local mass effect. A symptom that proves challenging to definitively manage is trigeminal neuralgia (TN), which occurs in approximately 5% of PCM cases. To date, there is no consensus on whether microsurgical resection or stereotactic radiosurgery (SRS) leads to better outcomes in the treatment of TN secondary to PCM. In this systematic review and meta-analysis, the authors aimed to evaluate the available literature on the efficacy of microsurgical resection versus SRS for controlling TN secondary to PCM.
The Embase, MEDLINE, Scopus, and Cochrane databases were queried from database inception to May 17, 2022, using the search terms "(petroclival AND meningioma) AND (trigeminal AND neuralgia)." Study inclusion criteria were as follows: 1) reports on patients aged ≥ 18 years and diagnosed with TN secondary to PCM, 2) cases treated with microsurgical resection or SRS, 3) cases with at least one posttreatment follow-up report of TN pain, 4) cases with at least one outcome of tumor control, and 5) publications describing randomized controlled trials, comparative or single-arm observational studies, case reports, or case series. Exclusion criteria were 1) literature reviews, technical notes, conference abstracts, or autopsy reports; 2) publications that did not clearly differentiate data on patients with PCMs from data on patients with different tumors or with meningiomas in different locations (other intracranial or spinal meningiomas); 3) publications that contained insufficient data on treatments and outcomes; and 4) publications not written in the English language. References of eligible studies were screened to retrieve additional relevant studies. Data on pain and tumor outcomes were compared between the microsurgical resection and SRS treatment groups. The DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction was used to pool estimates from the included studies.
Two comparative observational studies and 6 single-arm observational studies describing outcomes after primary intervention were included in the analyses (138 patients). Fifty-seven patients underwent microsurgical resection and 81 underwent SRS for the management of TN secondary to PCM. By the last follow-up (mean 71 months, range 24-149 months), the resection group had significantly higher rates of pain resolution than the SRS group (82%, 95% CI 50%-100% vs 31%, 95% CI 18%-45%, respectively; p = 0.004). There was also a significantly longer median time to tumor recurrence following resection (43.75 vs 16.7 months, p < 0.01). The resection group showed lower rates of pain persistence (0%, 95% CI 0%-6% vs 25%, 95% CI 13%-39%, p = 0.001) and pain exacerbation (0% vs 12%, 95% CI 3%-23%, p = 0.001). The most common postintervention Barrow Neurological Institute pain score in the surgical group was I (66.7%) compared with III (27.2%) in the SRS group. Surgical reintervention was less frequently required following primary resection (1.8%, 95% CI 0%-37% vs 19%, 95% CI 1%-48%, p < 0.01).
Microsurgical resection is associated with higher rates of TN pain resolution and lower rates of pain persistence and exacerbation than SRS in the treatment of PCM. SRS with further TN management is a viable alternative in patients who are not good candidates for microsurgical resection.
岩斜脑膜瘤(PCM)的治疗极具挑战性,因为它们位置深,靠近关键的神经血管结构。这些病变的患者通常因局部占位效应而出现症状。三叉神经痛(TN)是一种难以明确治疗的症状,约占 PCM 病例的 5%。迄今为止,对于 PCM 继发 TN 的治疗,显微切除术与立体定向放射外科(SRS)哪种方法的疗效更好,尚无共识。在这项系统评价和荟萃分析中,作者旨在评估显微切除术与 SRS 治疗 PCM 继发 TN 的疗效的相关文献。
从数据库建立到 2022 年 5 月 17 日,使用“(岩斜部和脑膜瘤)和(三叉神经和神经痛)”等检索词,在 Embase、MEDLINE、Scopus 和 Cochrane 数据库中进行检索。研究纳入标准如下:1)年龄≥18 岁且诊断为 PCM 继发 TN 的患者报告;2)接受显微切除术或 SRS 治疗的病例;3)至少有一次治疗后 TN 疼痛随访报告;4)至少有肿瘤控制结果的病例;5)描述随机对照试验、比较或单臂观察性研究、病例报告或病例系列的出版物。排除标准为:1)文献综述、技术说明、会议摘要或尸检报告;2)未明确将 PCM 患者的数据与来自不同肿瘤或颅内或脊柱脑膜瘤等其他部位脑膜瘤患者的数据区分开的出版物;3)包含关于治疗和结果的信息不足的出版物;4)非英文出版物。筛选合格研究的参考文献以检索其他相关研究。将疼痛和肿瘤结果的数据与显微切除术和 SRS 治疗组进行比较。使用 DerSimonian-Laird 随机效应模型和 Hartung-Knapp-Sidik-Jonkman 方差校正对纳入研究的估计值进行汇总。
分析纳入了 2 项比较观察性研究和 6 项描述初次干预后结果的单臂观察性研究(138 例患者)。57 例患者接受显微切除术,81 例患者接受 SRS 治疗 PCM 继发 TN。末次随访(平均 71 个月,范围 24-149 个月)时,切除术组的疼痛缓解率显著高于 SRS 组(82%,95%CI 50%-100%比 31%,95%CI 18%-45%,p=0.004)。切除组的肿瘤复发中位时间也明显更长(43.75 比 16.7 个月,p<0.01)。切除术组的疼痛持续率(0%,95%CI 0%-6%比 25%,95%CI 13%-39%,p=0.001)和疼痛加重率(0%比 12%,95%CI 3%-23%,p=0.001)较低。手术组中最常见的术后巴罗神经研究所疼痛评分是 I(66.7%),而 SRS 组是 III(27.2%)。初次切除后再次手术干预的频率较低(1.8%,95%CI 0%-37%比 19%,95%CI 1%-48%,p<0.01)。
在治疗 PCM 时,与 SRS 相比,显微切除术与更高的 TN 疼痛缓解率和更低的疼痛持续率和加重率相关。对于不适合显微切除术的患者,SRS 联合进一步的 TN 管理是一种可行的替代方法。